| 74802-0 |
Glucose challenge |
Imp |
Exhl gas |
Pt |
Nom |
|
|
ACTIVE |
Glucose challenge (hydrogen breath test) [Interpretation] in Exhaled gas |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHAL |
|
74802-0 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose HBT ExG-Imp |
|
|
|
|
|
Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Gases; Glu; Glu tol; Gluc; Glucose HBT; Glucose tolerance; Glucoseur; GTT; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Point in time; Random |
2.48 |
2.48 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 74803-8 |
Lactose challenge |
Imp |
Exhl gas |
Pt |
Nom |
|
|
ACTIVE |
Lactose challenge (breath test) [Interpretation] in Exhaled gas |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHAL |
|
74803-8 |
|
|
|
|
Observation |
|
|
|
0 |
Lactose BT ExG-Imp |
|
|
|
|
|
Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Gases; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Lactose BT; LTT; Nominal; Point in time; Random |
2.78 |
2.48 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: DefinitionDescription: Updated definition to include methane breath test; |
0 |
| 74804-6 |
Fructose challenge |
Imp |
Exhl gas |
Pt |
Nom |
|
|
ACTIVE |
Fructose challenge (hydrogen breath test) [Interpretation] in Exhaled gas |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHAL |
|
74804-6 |
|
|
|
|
Observation |
|
|
|
0 |
Fructose HBT ExG-Imp |
|
|
|
|
|
Breath; CHEMISTRY.CHALLENGE TESTING; ExG; Exhaled gas; Exhaled gas (=breath); Fructose HBT; Gases; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Levulose; Nominal; Point in time; Random; Revulose |
2.48 |
2.48 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 74805-3 |
Penicillium sp Ab.IgG |
MCnc |
Ser/Plas |
Pt |
Qn |
IA |
|
ACTIVE |
Penicillium sp IgG Ab [Mass/volume] in Serum or Plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
ALLERGY |
|
74805-3 |
|
IA |
|
|
Both |
|
|
|
0 |
Penicillium IgG IA-mCnc |
|
|
|
|
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; Gm27; IAA; Immune globulin G; Immunoglobulin G; Level; m27; Mass concentration; MEIA; Penicillium spp; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; RGm27; Rm217; SerP; SerPl; SerPlas; Serum; Serum or plasma; species; spp; SR; SUDS |
2.56 |
2.48 |
|
|
|
|
|
|
|
mg/L |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 74806-1 |
Lithium^trough |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Lithium [Moles/volume] in Serum or Plasma --trough |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
74806-1 |
|
|
|
|
Both |
|
|
|
0 |
Lithium Trough SerPl-sCnc |
|
|
|
|
|
Chemistry; Eskalith; Level; Li; Lithane; Pl; Plasma; Plsm; Point in time; Pre; Predose; Pre-dose; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.77 |
2.48 |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
| 74807-9 |
Transferrin receptor.soluble/log Ferritin index |
MRto |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Transferrin receptor.soluble/log Ferritin index [Mass Ratio] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ratio |
|
|
sTfR nmol/L/base-10 log Ferritin ng/mL |
|
|
|
CHEM |
|
74807-9 |
|
|
|
|
Both |
|
|
|
0 |
sTfR SerPl |
|
|
|
|
|
Chemistry; Ferr; Mass concentration ratio; Mass ratio; MCRto; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Rec; Recept; Receptors; Recp; Recptr; SerP; SerPl; SerPlas; Serum; Serum or plasma; Siderophilin; SR; sTfR; Tf; Trf; TRFRN |
2.48 |
2.48 |
|
|
|
|
|
|
|
{ratio} |
|
|
|
0 |
| 74808-7 |
von Willebrand factor.activity actual/Normal^immediately after 1:1 addition of normal plasma |
RelRto |
PPP |
Pt |
Qn |
IA |
|
ACTIVE |
von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay --immediately after 1:1 addition of normal plasma |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
COAG |
|
74808-7 |
|
IA |
|
|
Both |
|
|
|
0 |
vWf:Ac Act/Nor imm 1:1 NP PPP IA |
|
|
|
|
|
Act/Nor; Activ; Actvty; COAGULATION; Control; EIA; ELFA; ELISA; Enzyme immunoassay; Fac; Fact; Hematology; Heme; i; IAA; imm 1:1 NP; MEIA; Movements; Plas; Platelet poor plasma; Point in time; QNT; Quan; Quant; Quantitative; Random; Relative ratio; SUDS; Von will; Vonwillebrand; vWf; vWf:Ac |
2.73 |
2.48 |
|
|
|
|
|
|
|
% |
|
|
Renamed Method from "Imm" to "IA" for consistency across classes (approved by Laboratory LOINC Committee 2016 12). |
0 |
| 74809-5 |
von Willebrand factor.activity actual/Normal |
RelRto |
PPP^Control |
Pt |
Qn |
IA |
|
ACTIVE |
von Willebrand factor (vWf).activity actual/normal in Control Platelet poor plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
COAG |
|
74809-5 |
|
IA |
|
|
Observation |
|
|
|
0 |
vWf:Ac Act/Nor PPP Cont IA |
|
|
|
|
|
Act/Nor; Activ; Actvty; COAGULATION; Contrl; Control; EIA; ELFA; ELISA; Enzyme immunoassay; Fac; Fact; Hematology; Heme; IAA; MEIA; Movements; Normal; Plas; Platelet poor plasma; Point in time; QNT; Quan; Quant; Quantitative; Random; Relative ratio; SUDS; Von will; Vonwillebrand; vWf; vWf:Ac |
2.73 |
2.48 |
|
|
|
|
|
|
|
% |
|
|
Renamed Method from "Imm" to "IA" for consistency across classes (approved by Laboratory LOINC Committee 2016 12). |
0 |
| 7481-5 |
Maple red+Silver Ab.IgE |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Red+Silver Maple IgE Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
kIU/L |
|
|
|
|
|
|
ALLERGY |
|
7481-5 |
|
|
|
|
Both |
|
|
|
0 |
Red+Silver Maple IgE Qn |
|
|
|
Y |
|
ABS; Aby; Acer; Ag; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Immune globulin E; Immunoglobulin E; Point in time; QNT; Quan; Quant; Quantitative; Random; Red+Silver Maple; Serum; Silv; SR |
2.73 |
1.0h(2) |
|
|
|
|
|
|
|
k[IU]/L |
|
|
|
0 |
| 74810-3 |
Acetyl fentanyl |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
Acetyl fentanyl [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
74810-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Acetyl fentanyl Ur Ql Cfm |
|
|
|
|
|
Actiq; Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Desmethyl fentanyl; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Duragesic; Durogesic; Fenpat; fentanil; GCMS; hydrochloride; Illicit; LC/MS/MS; N- phenyl- N- [1- (2- phenylethyl)- 4- piperidinyl]- acetamide, monohydrochloride; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; Sublimaze; UA; UR; Urn |
2.73 |
2.48 |
|
|
|
|
|
|
|
|
|
|
Release 2.69: COMPONENT: Removed TALLMAN lettering because "Acetyl fentanyl" is not on the list of tall man drugs; Previous Releases: The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 74811-1 |
Dihydrocodeine |
MCnc |
Saliva |
Pt |
Qn |
Confirm |
|
ACTIVE |
Dihydrocodeine [Mass/volume] in Saliva (oral fluid) by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
74811-1 |
|
Confirm |
|
|
Both |
|
|
|
0 |
DHC Sal Cfm-mCnc |
|
|
|
|
|
Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DF-118; DHC; DHCPlus; Drocode; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Level; Mass concentration; Oral fluid; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Sal |
2.73 |
2.48 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 74812-9 |
Mirtazapine |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Mirtazapine [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
74812-9 |
|
|
|
|
Both |
|
|
|
0 |
Mirtazapine Ur Ql |
|
|
|
|
|
Avanza; DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Reflex; Remeron; Screen; UA; UR; Urn; Zispin |
2.73 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 74813-7 |
Nucleated cells |
NCnc |
Dial fld |
Pt |
Qn |
Manual count |
|
ACTIVE |
Nucleated cells [#/volume] in Dialysis fluid by Manual count |
|
MIN |
DefinitionDescription |
|
|
10*6/L |
|
|
|
|
|
|
HEM/BC |
|
74813-7 |
|
Manual count |
|
|
Both |
|
|
|
0 |
Nuc cell # Dial fld Manual |
|
|
|
|
|
#; ABS; absolute; absolutes; Cell; Cellularity; Cnt; Count; Count/volume; CT; Diaf; Dialysate; Dialysis fluid; HEMATOLOGY/CELL COUNTS; Manl; Nuc; Nuc cell; Number concentration; Number Concentration (count/vol); Point in time; QNT; Quan; Quant; Quantitative; Random |
2.48 |
2.48 |
|
|
|
|
|
|
|
10*6/L |
|
|
|
0 |
| 74814-5 |
Plasma cells.centroblasts/Leukocytes |
NFr |
Bld |
Pt |
Qn |
Manual count |
|
ACTIVE |
Plasma cells.centroblasts/Leukocytes in Blood by Manual count |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
74814-5 |
|
Manual count |
|
|
Both |
|
|
|
0 |
Plms centblst NFr Bld Manual |
|
|
|
|
|
Blood; Cell; Cellularity; HEMATOLOGY/CELL COUNTS; Leuc; Leuk; Leukocyte; Lkcs; Manl; Myeloma cells; Number fraction; Percent; Plasmacyte; Plasmacytes; Plms centblst; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; WBC; WBCs; White blood cell; White blood cells; Whole blood |
2.79 |
2.48 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 74815-2 |
Ascaris sp Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Ascaris sp IgG Ab [Presence] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74815-2 |
|
IA |
|
|
Both |
|
|
|
0 |
Ascaris IgG Ser Ql IA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Ordinal; p1; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; species; spp; SR; SUDS |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 74816-0 |
Bacteria |
Prid |
Eye |
Pt |
Nom |
Anaerobic+Aerobic culture |
|
ACTIVE |
Bacteria identified in Eye by Anaerobe+Aerobe culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74816-0 |
|
Anaerobic+Aerobic culture |
|
|
Observation |
|
|
|
0 |
Bacteria Eye Anaerobe+Aerobe Cult |
|
|
|
|
|
Aerobe; Aerobe Cult; Aerobed; Anaerobe+Aerobe Cult; Bact; C&S; Cult; Cultures; Eyeball; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; Occular; Oculis; Ophthalmologic; Optic globe; Point in time; Random; Vision; Visual |
2.78 |
2.48 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
| 74817-8 |
Desomorphine |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Desomorphine [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
74817-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Desom Ur Cfm-mCnc |
|
|
|
|
|
Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; crocodile; Dihydrodesoxymorphine; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; krokodil; LC/MS/MS; Level; Mass concentration; Permonid; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.48 |
2.48 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 74818-6 |
Desomorphine |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Desomorphine [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
74818-6 |
|
Screen |
|
|
Both |
|
|
|
0 |
Desom Ur Ql Scn |
|
|
|
|
|
Addiction; crocodile; Dihydrodesoxymorphine; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; krokodil; Ordinal; Permonid; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.73 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 74819-4 |
Promazine |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Promazine [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
74819-4 |
|
Screen |
|
|
Both |
|
|
|
0 |
Promazine Ur Ql Scn |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; Sparine; Tranquazine; UA; UR; Urn |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 7482-3 |
Maple sugar Ab.IgE |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Maple sugar IgE Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
kIU/L |
|
|
|
|
|
|
ALLERGY |
|
7482-3 |
|
|
|
|
Both |
|
|
|
0 |
Maple sugar IgE Qn |
|
|
|
Y |
|
ABS; Aby; Acer; Acer saccarum; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Immune globulin E; Immunoglobulin E; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.73 |
1.0h(2) |
|
|
|
|
|
|
|
k[IU]/L |
|
|
|
0 |
| 74820-2 |
Plasma cells.centrocytes/Leukocytes |
NFr |
Bld |
Pt |
Qn |
Manual count |
|
ACTIVE |
Plasma cells.centrocytes/Leukocytes in Blood by Manual count |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
74820-2 |
|
Manual count |
|
|
Both |
|
|
|
0 |
Plms centcyts NFr Bld Manual |
|
|
|
|
|
Blood; Cell; Cellularity; HEMATOLOGY/CELL COUNTS; Leuc; Leuk; Leukocyte; Lkcs; Manl; Myeloma cells; Number fraction; Percent; Plasmacyte; Plasmacytes; Plms centcyts; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; WBC; WBCs; White blood cell; White blood cells; Whole blood |
2.79 |
2.48 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 74821-0 |
Chikungunya virus Ab |
PrThr |
Ser |
Pt |
Ord |
HAI |
|
ACTIVE |
Chikungunya virus Ab [Presence] in Serum by Hemagglutination inhibition |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74821-0 |
|
HAI |
|
|
Both |
|
|
|
0 |
CHIKV Ab Ser Ql HAI |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; CHIKV; HEMAGGLUTINATION INHIBITION; HI; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 74822-8 |
Clostridioides difficile toxin B tcdB gene |
PrThr |
Stool |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Clostridioides difficile toxin B tcdB gene [Presence] in Stool by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74822-8 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
C diff Tox B tcdB Stl Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Bowel movement; C diff; C diff Tox; C diff Tox B; C diff Tox B tcdB; C difficile; Clostridium difficile; DNA NUCLEIC ACID PROBE; DNA probe; Faecal; Faeces; Fecal; Feces; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Stl; Stool = Fecal; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.73 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; Added "tcdB gene" to the Component since this assay detects nucleic acids within the tcdB gene of C. difficile; Updated genus name from Clostridium to Clostridioides based on current (2019) accepted nomenclature for this genus [PMID:27370902]. |
0 |
| 74823-6 |
Jamestown canyon virus Ab |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Jamestown canyon virus Ab [Presence] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74823-6 |
|
IA |
|
|
Both |
|
|
|
0 |
JCV Ab Ser Ql IA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Infectious Disease; InfectiousDisease; JCV; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SUDS |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 74824-4 |
Powassan virus Ab |
PrThr |
Ser |
Pt |
Ord |
HAI |
|
ACTIVE |
Powassan virus Ab [Presence] in Serum by Hemagglutination inhibition |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74824-4 |
|
HAI |
|
|
Both |
|
|
|
0 |
POWV Ab Ser Ql HAI |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Hemagglutination inhibition; HI; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; POWV; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
